Citations (85)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Stephanie A. Smith, Richard J. Travers & James H. Morrissey. (2015) How it all starts: Initiation of the clotting cascade. Critical Reviews in Biochemistry and Molecular Biology 50:4, pages 326-336.
Read now
Read now
Meyer-Michel Samama, Jean Amiral, Céline Guinet, Léna Le Flem & Jerard Seghatchian. (2013) Monitoring plasma levels of factor Xa inhibitors: how, why and when?. Expert Review of Hematology 6:2, pages 155-164.
Read now
Read now
Peter P. Toth. (2012) Practical Management of Anticoagulants in Family Medicine after Orthopedic Surgery. Postgraduate Medicine 124:4, pages 206-214.
Read now
Read now
Jeffrey I Weitz & Lori-Ann Linkins. (2007) Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opinion on Investigational Drugs 16:3, pages 271-282.
Read now
Read now
Peter A Kouides & William Fricke. (2005) Diagnosis and management of heparin-induced thrombocytopenia. Expert Review of Cardiovascular Therapy 3:2, pages 335-345.
Read now
Read now
Johannes Ruef & Hugo A Katus. (2003) New antithrombotic drugs on the horizon. Expert Opinion on Investigational Drugs 12:5, pages 781-797.
Read now
Read now
Sheila A Doggrell. (2003) Reviparin as prophylaxis for thromboembolism after leg injury and hip replacement. Expert Opinion on Pharmacotherapy 4:2, pages 285-288.
Read now
Read now
Sheila A Doggrell. (2002) Fondaparinux versus enoxaparin for the prevention of venous thromboembolism. Expert Opinion on Pharmacotherapy 3:4, pages 455-457.
Read now
Read now
Articles from other publishers (77)
Antonella Bisio, Marco Guerrini & Annamaria Naggi. 2023. Carbohydrate‐Based Therapeutics. Carbohydrate‐Based Therapeutics
353
380
.
Lukas Wettstein, Patrick Immenschuh, Tatjana Weil, Carina Conzelmann, Yasser Almeida‐Hernández, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Rishikesh Lotke, Moritz Petersen, Steffen Stenger, Frank Kirchhoff, Daniel Sauter, Stefan Pöhlmann, Elsa Sanchez‐Garcia & Jan Münch. (2022) Native and activated antithrombin inhibits TMPRSS2 activity and SARS‐CoV‐2 infection. Journal of Medical Virology 95:1.
Crossref
Crossref
Liangwei Zhang, Yating Liu, Zhuojia Xu, Tianhui Hao, Peng George Wang, Wei Zhao & Tiehai Li. (2022) Design and Synthesis of Neutralizable Fondaparinux. JACS Au 2:12, pages 2791-2799.
Crossref
Crossref
Marco Heestermans, Géraldine Poenou, Hind Hamzeh-Cognasse, Fabrice Cognasse & Laurent Bertoletti. (2022) Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells 11:20, pages 3214.
Crossref
Crossref
Li-Yu Chen, Nida Khan, Annerose Lindenbauer & Thi-Huong Nguyen. (2022) When Will Fondaparinux Induce Thrombocytopenia?. Bioconjugate Chemistry 33:8, pages 1574-1583.
Crossref
Crossref
Prabhu Kumar K.M.Vasantha Kumar B.C.Sharath Kumar M.N.Raghavendra Kumar P.Devaraju S.Butcher R.J.Revanasiddappa H.D.. (2021) Synthesis, structural characterization, CT-DNA interaction study and antithrombotic activity of new ortho-vanillin-based chiral (Se,N,O) donor ligands and their Pd complexes. Inorganica Chimica Acta 528, pages 120609.
Crossref
Crossref
Deling Shi, Anran Sheng & Lianli Chi. (2021) Glycosaminoglycan-Protein Interactions and Their Roles in Human Disease. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Nigel Mackman, Wolfgang Bergmeier, George A. Stouffer & Jeffrey I. Weitz. (2020) Therapeutic strategies for thrombosis: new targets and approaches. Nature Reviews Drug Discovery 19:5, pages 333-352.
Crossref
Crossref
Jonathan Cramer, Christoph P. Sager & Beat Ernst. (2019) Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group. Journal of Medicinal Chemistry 62:20, pages 8915-8930.
Crossref
Crossref
Dustin R. Klein, Franklin E. LeachIIIIII, I. Jonathan Amster & Jennifer S. Brodbelt. (2019) Structural Characterization of Glycosaminoglycan Carbohydrates Using Ultraviolet Photodissociation. Analytical Chemistry 91:9, pages 6019-6026.
Crossref
Crossref
Hannah E. Caputo, John E. Straub & Mark W. Grinstaff. (2019) Design, synthesis, and biomedical applications of synthetic sulphated polysaccharides. Chemical Society Reviews 48:8, pages 2338-2365.
Crossref
Crossref
Yiran Zhang, Meng Zhang, Lijuan Tan, Nana Pan & Lijuan Zhang. 2019. Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B. Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B
41
53
.
Meng Zhang, Huaiqian Dou, Dandan Yang, Ming Shan, Xiulian Li, Cui Hao, Yiran Zhang, Pengjiao Zeng, Yanli He, Yong Liu, Jing Fu, Wei Wang, Minghui Hu, Hui Li, Qingwu Tian, Shuhe Lei & Lijuan Zhang. 2019. Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A. Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A
141
163
.
Swaroop S. Kumar & Abdulhameed Sabu. 2019. Therapeutic Enzymes: Function and Clinical Implications. Therapeutic Enzymes: Function and Clinical Implications
345
381
.
Masato Kobayashi, Masahiko Akatsu, Yoshihisa Fujita & Koichi Nishikawa. (2018) Successful perioperative management of a patient with erythropoietin-producing uterine myoma. JA Clinical Reports 4:1.
Crossref
Crossref
Stella Salta, Loula Papageorgiou, Annette K. Larsen, Patrick Van Dreden, Claire Soulier, Dennis V. Cokkinos, Ismail Elalamy & Grigoris T. Gerotziafas. (2018) Comparison of antithrombin‐dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots. Research and Practice in Thrombosis and Haemostasis 2:4, pages 696-707.
Crossref
Crossref
Flávia S Frattani, Lidia M Lima, Eliezer J Barreiro & Russolina B Zingali. (2017) The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats. Journal of Pharmacy and Pharmacology 69:10, pages 1374-1380.
Crossref
Crossref
Soo Lee, Wonhwa Lee, ThiHa Nguyen, Il Um, Jong-Sup Bae & Eunsook Ma. (2017) Synthesis and Thrombin, Factor Xa and U46619 Inhibitory Effects of Non-Amidino and Amidino N2-Thiophenecarbonyl- and N2-Tosylanthranilamides. International Journal of Molecular Sciences 18:6, pages 1144.
Crossref
Crossref
Sylvain Rocheleau, Joshua Pottel, Igor Huskić & Nicolas Moitessier. (2017) Highly Regioselective Monoacylation of Unprotected Glucopyranoside Using Transient Directing-Protecting Groups. European Journal of Organic Chemistry 2017:3, pages 646-656.
Crossref
Crossref
Maiko Yuri, Yoko Tabe, Koji Tsuchiya, Ryo Sadatsuki, Jun Aoki, Takashi Horii, Toshiaki Iba & Akimichi Ohsaka. (2015) Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. Clinical and Applied Thrombosis/Hemostasis 22:5, pages 453-458.
Crossref
Crossref
Soo Lee, Wonhwa Lee, Jong-Sup Bae & Eunsook Ma. (2016) Synthesis and in Vitro and in Vivo Anticoagulant and Antiplatelet Activities of Amidino- and Non-Amidinobenzamides. Molecules 21:5, pages 676.
Crossref
Crossref
Xiang Dai, Wentao Liu, Qilong Zhou, Chunwei Cheng, Chao Yang, Shuqing Wang, Min Zhang, Pei Tang, Hao Song, Dan Zhang & Yong Qin. (2015) Formal Synthesis of Anticoagulant Drug Fondaparinux Sodium. The Journal of Organic Chemistry 81:1, pages 162-184.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
428
432
.
Mashio Nakamura, Norikazu Yamada & Masaaki Ito. (2015) Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy. Journal of Cardiology 66:6, pages 451-459.
Crossref
Crossref
S. Peraramelli, S. Thomassen, A. Heinzmann, T. M. Hackeng, R. Hartmann, F. Scheiflinger, M. Dockal & J. Rosing. (2015) Role of exosite binding modulators in the inhibition of Fxa by TFPI. Thrombosis and Haemostasis 115:3, pages 580-590.
Crossref
Crossref
Baolin Wu, Na Wei, Vireak Thon, Mohui Wei, Zaikuan Yu, Yongmei Xu, Xi Chen, Jian Liu, Peng George Wang & Tiehai Li. (2015) Facile chemoenzymatic synthesis of biotinylated heparosan hexasaccharide. Organic & Biomolecular Chemistry 13:18, pages 5098-5101.
Crossref
Crossref
Jawed Fareed, Evi Kalodiki & Debra Hoppensteadt. 2014. Urgent Interventional Therapies. Urgent Interventional Therapies
27
40
.
Martin KreimannSven BrandtKrystin KrauelStephan BlockChristiane A. Helm, Werner Weitschies, Andreas GreinacherMihaela Delcea. (2014) Binding of anti–platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood 124:15, pages 2442-2449.
Crossref
Crossref
Cheng‐Hsiu Chang, Larry S. Lico, Teng‐Yi Huang, Shu‐Yi Lin, Chi‐Liang Chang, Susan D. Arco & Shang‐Cheng Hung. (2014) Synthesis of the Heparin‐Based Anticoagulant Drug Fondaparinux. Angewandte Chemie International Edition 53:37, pages 9876-9879.
Crossref
Crossref
Cheng-Hsiu Chang, Larry S. Lico, Teng-Yi Huang, Shu-Yi Lin, Chi-Liang Chang, Susan D. Arco & Shang-Cheng Hung. (2014) Synthesis of the Heparin-Based Anticoagulant Drug Fondaparinux. Angewandte Chemie 126:37, pages 10034-10037.
Crossref
Crossref
Lauri Virtanen, Birgitta Salmela, Jari Leinonen, Marja Lemponen, Jukka Huhtala, Lotta Joutsi-Korhonen & Riitta Lassila. (2014) Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement. Blood Coagulation & Fibrinolysis 25:6, pages 597-603.
Crossref
Crossref
Tiehai Li, Hui Ye, Xuefeng Cao, Jiajia Wang, Yonghui Liu, Lifei Zhou, Qiang Liu, Wenjun Wang, Jie Shen, Wei Zhao & Peng Wang. (2014) Total Synthesis of Anticoagulant Pentasaccharide Fondaparinux. ChemMedChem 9:5, pages 1071-1080.
Crossref
Crossref
Nick van Es, Suzanne M. Bleker, Harry R. Büller & Michiel Coppens. (2013) New developments in parenteral anticoagulation for arterial and venous thromboembolism. Best Practice & Research Clinical Haematology 26:2, pages 203-213.
Crossref
Crossref
Sebastian Harder. (2013) Renal Profiles of Anticoagulants. The Journal of Clinical Pharmacology 52:7, pages 964-975.
Crossref
Crossref
Stephanie Ann Smith. (2012) Antithrombotic Therapy. Topics in Companion Animal Medicine 27:2, pages 88-94.
Crossref
Crossref
Meyer Michel Samama. (2011) The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thrombosis Research 127:6, pages 497-504.
Crossref
Crossref
Hannes G. Wallnoefer, Klaus R. Liedl & Thomas Fox. (2011) A challenging system: Free energy prediction for factor Xa. Journal of Computational Chemistry 32:8, pages 1743-1752.
Crossref
Crossref
M. Wolzt, M. M. Samama, S. Kapiotis, K. Ogata, J. Mendell & S. Kunitada. (2011) Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thrombosis and Haemostasis 105:6, pages 1080-1090.
Crossref
Crossref
Walter P Jeske, Jeanine M Walenga, Meyer M Samama, Debra Hoppensteadt, Myttle Mayuga & Jawed Fareed. (2011) Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Blood Coagulation & Fibrinolysis 22:3, pages 206-210.
Crossref
Crossref
Meyer M. Samama & Céline Guinet. (2011) Laboratory assessment of new anticoagulants. Clinical Chemistry and Laboratory Medicine 49:5.
Crossref
Crossref
Jawed Fareed, Cafer Adiguzel & Indermohan Thethi. (2011) Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thrombosis Journal 9:1, pages 5.
Crossref
Crossref
Ali Zalpour, Michael H. Kroll, Vahid Afshar-Kharghan, Syed Wamique Yusuf & Carmen Escalante. (2011) Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data?. Advances in Hematology 2011, pages 1-12.
Crossref
Crossref
Sun Hee Park, Rui Jiang, Shunfu Piao, Bing Zhang, Eun-Hye Kim, Hyun-Mi Kwon, Xiao Ling Jin, Bok Luel Lee & Nam-Chul Ha. (2011) Structural and Functional Characterization of a Highly Specific Serpin in the Insect Innate Immunity. Journal of Biological Chemistry 286:2, pages 1567-1575.
Crossref
Crossref
Richard Montagnac, Saïd Brahimi, Pascale Janian, Jean-Pierre Melin, Jean-Philippe Bertocchio & Alain Wynckel. (2010) Intérêt du fondaparinux (Arixtra®) en hémodialyse dans les thrombopénies induites par l’héparine de type II (TIH II). À propos d’une nouvelle observation. Néphrologie & Thérapeutique 6:7, pages 581-584.
Crossref
Crossref
Sam Schulman. 2009. New Therapeutic Agents in Thrombosis and Thrombolysis. New Therapeutic Agents in Thrombosis and Thrombolysis
155
170
.
Leszek Czerchawski & Wojciech Witkiewicz. (2009) New Anticoagulants in Clinical Practice. Polish Journal of Surgery 81:6.
Crossref
Crossref
. 2009. MeylerâÂÂs Side Effects of Cardiovascular Drugs. MeylerâÂÂs Side Effects of Cardiovascular Drugs
449
556
.
Martin de Kort, Bas Gianotten, Jeffry A. J. Wisse, Ebo S. Bos, Michel H. M. Eppink, Ellen Mattaar, Gerard M. T. Vogel, Wim H. A. Dokter, Maarten Honing, Stanislava Vonsovic, Martin-Jan Smit, Jac C. H. M. Wijkmans & Constant A. A. van Boeckel. (2008) Conjugation of ATIII-Binding Pentasaccharides to Extend the Half-Life of Proteins: Long-Acting Insulin. ChemMedChem 3:8, pages 1189-1193.
Crossref
Crossref
Stephen P. O’Connor, Karnail Atwal, Chi Li, Eddie C.-K. Liu, Steven M. Seiler, Mengxiao Shi, Yan Shi, Philip D. Stein & Ying Wang. (2008) Synthesis and evaluation of acylguanidine FXa inhibitors. Bioorganic & Medicinal Chemistry Letters 18:16, pages 4696-4699.
Crossref
Crossref
Job Harenberg, Ingrid Jörg, Yvonne Vukojevic, Gerd Mikus & Christel Weiss. (2008) Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. European Journal of Clinical Pharmacology 64:6, pages 555-563.
Crossref
Crossref
P.C. WONG, E.J. CRAIN, B. XIN, R.R. WEXLER, P.Y.S. LAM, D.J. PINTO, J.M. LUETTGEN & R.M. KNABB. (2008) Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. Journal of Thrombosis and Haemostasis 6:5, pages 820-829.
Crossref
Crossref
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
DAVID BERGQVIST. 2007. The Vein Book. The Vein Book
347
351
.
Don T Elmore, Imre Sovago, Etelka Farkas, Avril Higton, Weng Chan, Botond Penke, Gabor Toth & Gyorgyi VaradiBotond Penke, Gábor Tóth & Györgyi Váradi. 2006. Amino Acids, Peptides and Proteins. Amino Acids, Peptides and Proteins
129
271
.
Shannon M. Bates & Jeffrey I. Weitz. (2006) The status of new anticoagulants. British Journal of Haematology 134:1, pages 3-19.
Crossref
Crossref
. 2006. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
1437
1439
.
J.I. WEITZ & S.M. BATES. (2005) New anticoagulants. Journal of Thrombosis and Haemostasis 3:8, pages 1843-1853.
Crossref
Crossref
K. Olanders, A. Borjesson, X. Zhao & R. Andersson. (2005) Effects of anticoagulant treatment on intestinal ischaemia and reperfusion injury in rats. Acta Anaesthesiologica Scandinavica 49:4, pages 517-524.
Crossref
Crossref
Shannon M Bates & Jeffrey I Weitz. (2005) New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. British Journal of Pharmacology 144:8, pages 1017-1028.
Crossref
Crossref
P. Bramlage, D. Pittrow & W. Kirch. (2005) Current concepts for the prevention of venous thromboembolism. European Journal of Clinical Investigation 35:s1, pages 4-11.
Crossref
Crossref
Rodger L. Bick, Eugene P. Frenkel, Jeanine Walenga, Jawed Fareed & Deborah A. Hoppensteadt. (2005) Unfractionated Heparin, Low Molecular Weight Heparins, and Pentasaccharide: Basic Mechanism of Actions, Pharmacology, and Clinical Use. Hematology/Oncology Clinics of North America 19:1, pages 1-51.
Crossref
Crossref
Eugene P. Frenkel, Yu-Min Shen & Barbara B. Haley. (2005) The Direct Thrombin Inhibitors: Their Role and Use for Rational Anticoagulation. Hematology/Oncology Clinics of North America 19:1, pages 119-145.
Crossref
Crossref
M. Tobu, Q. Ma, O. Iqbal, C. Schultz, W. Jeske, D. A. Hoppensteadt & J. Fareed. (2016) Comparative Tissue Factor Pathway Inhibitor Release Potential of Heparins. Clinical and Applied Thrombosis/Hemostasis 11:1, pages 37-47.
Crossref
Crossref
Jeffrey I. Weitz, Jack Hirsh & Meyer M. Samama. (2004) New Anticoagulant Drugs. Chest 126:3, pages 265S-286S.
Crossref
Crossref
Nick R. Bijsterveld, Roel Vink, Benien E. Van Aken, Hein Fennema, Ron J. G. Peters, Joost C. M. Meijers, Harry R. Büller & Marcel Levi. (2004) Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. British Journal of Haematology 124:5, pages 653-658.
Crossref
Crossref
K. Peerlinck. 2004.
358
361
.
Grigoris T Gerotziafas, Ismail Elalamy, François Depasse, Tahar Chakroun, Lucienne Bara, Pantelis Arzoglou & Meyer M Samama. (2003) On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasma. Blood Coagulation & Fibrinolysis 14:7, pages 633-638.
Crossref
Crossref
Jeanine M. Walenga, Walter P. Jeske, Peter Bacher & Jawed Fareed. 2001. Kirk-Othmer Encyclopedia of Chemical Technology. Kirk-Othmer Encyclopedia of Chemical Technology.
Shaker A. Mousa, Jeffrey Bozarth & Jeffrey S. Barrett. (2003) Pharmacodynamic Properties of the Low Molecular Weight Heparin, Tinzaparin: Effect of Molecular Weight Distribution on Plasma Tissue Factor Pathway Inhibitor in Healthy Human Subjects. The Journal of Clinical Pharmacology 43:7, pages 727-734.
Crossref
Crossref
L Lalourcey. (2003) THE DESIGN OF VENOUS THROMBOEMBOLISM PROPHYLAXIS TRIALS: IS ENOXAPARIN MORE EFFECTIVE THAN FONDAPARINUX?. International Journal of Clinical Practice 57:4, pages 289-294.
Crossref
Crossref
Debra Hoppensteadt, Jeanine M. Walenga, Jawed Fareed & Rodger L. Bick. (2003) Heparin, low–molecular-weight heparins, and heparin pentasaccharide. Hematology/Oncology Clinics of North America 17:1, pages 313-341.
Crossref
Crossref
Harry L Messmore, Walter P Jeske, William H Wehrmacher & Jeanine M Walenga. (2003) Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia. Drug Safety 26:9, pages 625-641.
Crossref
Crossref
Cécile Boyer-Joubert, Edwige Lorthiois & François Moreau. 2003.
347
374
.
Monica S. Da Silva & Michael Sobel. (2002) Anticoagulants: To bleed or not to bleed, that is the question. Seminars in Vascular Surgery 15:4, pages 256-267.
Crossref
Crossref
Nicola Volpi & Francesca Maccari. (2002) Detection of submicrogram quantities of glycosaminoglycans on agarose gels by sequential staining with toluidine blue and Stains‐All. ELECTROPHORESIS 23:24, pages 4060-4066.
Crossref
Crossref